Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer
Tanya B. Dorff, Bryan Goldman, Jacek K. Pinski, Philip C. Mack, Primo N. Lara, Peter J. Van Veldhuizen, David I. Quinn, Nicholas J. Vogelzang, Ian M. Thompson, Maha H.A. Hussain
Resultado de la investigación: Article › revisión exhaustiva
Profundice en los temas de investigación de 'Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer'. En conjunto forman una huella única.